Form4insider filings, from the source

SEC Form 4 · accession 0001835458-26-000012

Kiniksa Pharmaceuticals International, plc · KNSA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Mark Ragosa
Officer — CHIEF FINANCIAL OFFICER
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:49 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001730430

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Class A Ordinary ShareF1Sep 1, 2026M2,694—A18,848D
Class A Ordinary ShareF1Sep 1, 2026M1,750—A20,598D
Class A Ordinary ShareF1Sep 1, 2026M1,591—A22,189D
Class A Ordinary ShareF1Sep 1, 2026M3,069—A25,258D
Class A Ordinary ShareSep 1, 2026F4,404$79.28D20,854D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Share UnitF1,F2—Sep 1, 2026A7,800A——Class A Ordinary Share7,8007,800D
Share OptionF3$79.28Sep 1, 2026A31,150A—Aug 31, 2036Class A Ordinary Share31,15031,150D
Restricted Share UnitF1,F4,F2—Sep 1, 2026M3,069D——Class A Ordinary Share3,0699,206D
Restricted Share UnitF1,F5—Sep 1, 2026M1,591D——Class A Ordinary Share1,5913,182D
Restricted Share UnitF1,F6—Sep 1, 2026M1,750D——Class A Ordinary Share1,7501,750D
Restricted Share UnitF1,F7—Sep 1, 2026M2,694D——Class A Ordinary Share2,6940D

Explanation of responses